Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
TLR4, an important Toll-like receptor in innate immunity, can be activated by LPS and induce proinflammatory cytokines to resist invasion of pathogenic microorganism, but excessive inflammation can trigger tissue injury. Many genes negatively regulate TLR4 signaling pathway. Recent studies found that
malignant fibrous histiocytoma amplified sequence 1
(
MFHAS1
) suppressed the expression of cytokine IL6 in Raw264.7 cells stimulated by LPS, but the mechanisms remained unclear. This study investigated the role of
MFHAS1
in TLR4 signaling pathway and the possible mechanisms implicated. The results indicated that the expression of
MFHAS1
was significantly increased in cells stimulated with LPS. Up-regulation of
MFHAS1
effectively suppressed inflammatory cytokine expression in cells exposed to LPS, whereas down-regulation of
MFHAS1
markedly increased inflammatory cytokines expression. Co-immunoprecipitation, pull-down and immunofluorescence tests demonstrated that
MFHAS1
combined with the B and C subunits of PP2A and induced cytoplasm translocation of the C subunit, leading to decrease dephosphorylation of
c-Jun
at Thr239 and increase degradation of
c-Jun
. Reduction of
c-Jun
protein results in decreased AP-1 activity, which is independent of inhibition of JNK or p38MAPK phosphorylation. Taken together, these results indicate that
MFHAS1
suppresses TLR4 signaling pathway through induction of PP2A C subunit cytoplasm translocation and subsequent
c-Jun
degradation, leading finally to decrease AP-1 activity and cytokines expression.
...
PMID:MFHAS1 suppresses TLR4 signaling pathway via induction of PP2A C subunit cytoplasm translocation and inhibition of c-Jun dephosphorylation at Thr239. 2860 14